Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Manufacturer's response to case reports of PML.

× No keyword cloud information.

41 in total

Review 1. Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1-Mechanisms, Efficacy, and Safety.

Authors: C McNamara; G Sugrue; B Murray; P J MacMahon
Journal: AJNR Am J Neuroradiol Date: 2017-04-13 Impact factor: 3.825

2. A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.

Authors: Salim Chahin; Joseph R Berger
Journal: J Neurovirol Date: 2014-11-18 Impact factor: 2.643

3. [Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].

Authors: A Winkelmann; M Löbermann; E C Reisinger; H-P Hartung; U K Zettl
Journal: Nervenarzt Date: 2015-08 Impact factor: 1.214

Review 4. Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.

Authors: Jiwon Oh; Paul W O'Connor
Journal: CNS Drugs Date: 2013-08 Impact factor: 5.749

5. Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis.

Authors: Muriel Stoppe; Eva Thomä; Uwe Gerd Liebert; Eugene O Major; Karl-Titus Hoffmann; Joseph Claßen; Florian Then Bergh
Journal: J Neurol Date: 2014-03-18 Impact factor: 4.849

Review 6. Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview.

Authors: Roberto Bomprezzi
Journal: Ther Adv Neurol Disord Date: 2015-01 Impact factor: 6.570

Review 7. Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors: Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal: Nat Rev Neurol Date: 2016-03-04 Impact factor: 42.937

Review 8. Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.

Authors: A Salmen; R Gold; A Chan
Journal: Clin Exp Immunol Date: 2014-05 Impact factor: 4.330

Review 9. Infection risk in patients on multiple sclerosis therapeutics.

Authors: Eric M Williamson; Joseph R Berger
Journal: CNS Drugs Date: 2015-03 Impact factor: 5.749

10. Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.

Authors: Jonathan Zurawski; Ashley Flinn; Lindsay Sklover; Jacob A Sloane
Journal: J Neurol Date: 2016-05-18 Impact factor: 4.849